1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Renal cancer

Pembrolizumab with axitinib for untreated advanced renal cell carcinoma

Technology appraisal guidance [TA650] Published: 30 September 2020

Register as a stakeholder
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

History

A list of downloadable documents created during development.

Expected publication

  • Equality Impact Assessment (Guidance development) PDF 158 KB 30 September 2020  

Declaration of interests

  • Register of interests PDF 138 KB 30 September 2020  

Final draft guidance

  • Final draft guidance  
  • Final appraisal document PDF 237 KB 27 August 2020  
  • Committee papers PDF 1.27 MB 27 August 2020  
  • Public committee slides PDF 1.46 MB 27 August 2020  

Draft guidance

  • Draft guidance  
  • Appraisal consultation document (PDF version) PDF 292 KB 12 February 2020  
  • Appraisal consultation document (online commenting)  
  • Committee papers PDF 5.31 MB 12 February 2020  
  • Public committee slides PDF 2.05 MB 12 February 2020  

Invitation to participate

  • Final stakeholder list PDF 188 KB 17 May 2019  
  • NICE's response to comments on the draft scope and provisional stakeholder list PDF 313 KB 17 May 2019  
  • Equality impact assessment (Scoping) PDF 129 KB 17 May 2019  
  • Final scope PDF 348 KB 21 May 2019  

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

  • Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators  
  • Draft scope post referral PDF 527 KB 04 July 2018  
  • Draft matrix post referral PDF 260 KB 04 July 2018